 SAN DIEGO, Oct. 29, 2020 GLOBE NEWSWIRE -- Turning Point Therapeutics, Inc. Nasdaq: TPTX, a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the closing of its previously announced underwritten public offering of 5,287,357 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 689,655 shares, at a price to the public of 87.00 per share. The gross proceeds to Turning Point from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Turning Point, were approximately 460.0 million. 